SCHEMBL19475450

SCHEMBL19475450

C=CCn1c(CCCC)nc(C#N)c1-c1ccc(C(=O)OC)cc1N

nearest known ligand 0.43

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 17/20 0.43
TLR8 Q9NR97 10/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14744585 0.86 TLR7 (0.56) TLR7TLR8
SCHEMBL19180161 0.81 TLR7 (0.42) TLR7TLR8
SCHEMBL17181391 0.74 TLR7 (0.45) TLR7TLR8
SCHEMBL19475500 0.71 TLR7 (0.77) TLR7TLR8
SCHEMBL19475180 0.71 ALDH1A1 (0.37) TLR7TLR8
SCHEMBL15902487 0.66 KDM4E (0.39) TLR7
SCHEMBL1301770 0.65 TLR7 (0.46) TLR7TLR8
SCHEMBL19204368 0.65 TLR7 (0.36) TLR7TLR8
SCHEMBL9122418 0.64 AGTR1 (0.58) TLR7TLR8
SCHEMBL7997079 0.64 KDM4E (0.54) TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190127368-A1 NLRP3 MODULATORS IFM THERAPEUTICS INC (US) 2019-05-02 US disclosed
US-20190127368-A1 NLRP3 MODULATORS IFM THERAPEUTICS INC (US) 2019-05-02 US disclosed
WO-2017184735-A1 NLRP3 MODULATORS IFM THERAPEUTICS, INC (US) 2017-10-26 WO disclosed
WO-2017184735-A1 NLRP3 MODULATORS IFM THERAPEUTICS, INC (US) 2017-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127368-A1 NLRP3 MODULATORS NLRP3, TLR7, TLR8 TLR7 2/4885TLR8 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.